The action of p38 MAP kinase and its inhibitors on endometriosis

Yaoxue Xuebao

Volumn 45, Issue 5, 2010, Pages 548-554

  Zhou, Wei Dong ^a   Chen, Qiong Hua ^a   Chen, Qing Xi ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Endometriosis; Estrogen; Inhibitor; p38 MAP kinase

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; CYCLOOXYGENASE 2; DORAMAPIMOD; EMODIN; FLUINDOSTATIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIGUSTILIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RO 3201195; SB 681323; SCIO 469; SEX HORMONE; STROMELYSIN; TAK 715; TANGERETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VX 702;

ANGINA PECTORIS; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; DIABETES MELLITUS; DRUG MECHANISM; ENDOMETRIOSIS; HUMAN; IRRITABLE COLON; LUNG CANCER; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENDOMETRIOSIS; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; INFLAMMATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; PYRIDINES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954601563     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases [J]. Science, 2002, 298: 1911-1912.
2. Song JQ, Chen XC, Zhang J, et al. JNK/p38MAPK involves in ginsenoside Rb1 attenuating beta-amyloid peptide (25-35)-induced tau prote in hyperphosphorylation in embryo rat cortical neurons [J]. Acta Pharm Sin, 2008, 43: 29-34.
3. Ono K, Han J. The p38 signal transduction pathway - activation and function [J]. Cell Signal, 2000, 12: 1-13. (Pubitemid 30017963)
4. New L, Han J. The p38 MAP kinase pathway and its biological function [J]. Trends Cardiovas Med, 1998, 8: 220-228. (Pubitemid 28345826)
5. Johns DG, Ao Z, Willette RN, et al. Role of p38 MAP kinase in postcapillary venule leukocyte adhesion induced by ischemia/reperfusion injury [J]. Pharmacol Res, 2005, 51: 463-471. (Pubitemid 40321015)
6. Kaur J, Woodman RC, Kubes P. P38 MAPK: critical molecule in thrombin-induced NF-κB-dependent leukocyte recruitment [J]. Am J Physiol Heart Circ Physiol, 2003, 284: H1095-H1103.
7. Woo CH, Lim JH, Kim JH. VCAM-1 upregulation via PKCδ-p38 kinase-linked cascade mediates the TNF-α-induced leukocyte adhesion and emigration in the lung airway epithelium [J]. Am J Physiol Lung Cell Mol Physiol, 2005, 288: L307-L316.
8. Lee YB, Schrader JW, Kim SU. p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms [J]. Cytokine, 2000, 12: 874-880.
9. Lee SJ, Park SS, Lee US, et al. Signaling pathway for TNF-α-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells [J]. Int Immunopharmacol, 2008, 8: 1821-1826.
10. Cao W, Cheng L, Behar J, et al. IL-1β signaling in cat lower esophageal sphincter circular muscle [J]. Am J Physiol Gastrointest Liver Physiol, 2006, 291: G672-G680.
11. Studer RK, Gilbertson LG, Georgescu H, et al. p38 MAPK inhibition modulates rabbit nucleus pulposus cell response to IL-1 [J]. J Orthop Res. 2008, 26: 991-998.
12. Sun H, Xu B, Inoue H, et al. p38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes [J]. Cell Signal, 2008, 20: 1952-1959.
13. Wu MH, Wang CA, Lin CC, et al. Distinct regulation of cyclooxygenase-2 by interleukin-1β in normal and endometriotic stromal cells [J]. J Clin Endocrinol Metab, 2005, 90: 286-295.
14. Anette L, Ursula BL, Vibeke R, et al. Biochemical evaluation of endometrial function at the time of implantation [J]. Fertil Steril, 2002, 78: 221-233.
15. Kelly RW, King AE, Critchley HO. Cytokine control in human endometrium [J]. Reproduction, 2001, 121: 3-19.
16. Berkkanoglu M, Arici A. Immunology and endometriosis [J]. Am J Reprod Immunol, 2003, 50: 48-59.
17. Seval Y, Cakmak H, Kayisli UA, et al. Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium [J]. J Clin Endocrinol Metab, 2006, 91: 2349-2357.
18. Yoshino O, Osuga Y, Hirota Y, et al. Endometrial stromal cells undergoing decidualization down-regulate their properties to produce proinflammatory cytokines in response to interleukin-1β via reduced p38 mitogen-activated protein kinase phosphorylation [J]. J Clin Endocrinol Metab, 2003, 88: 2236-2241.
19. Yoshino O, Osuga Y, Hirota Y, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis [J]. Am J Reprod Immunol, 2004, 52: 306-311.
20. Kayisli UA, Cakmak H, Seval Y, et al. In vivo regulation of p38 MAPK activation in human endometrium and endometriosis [J]. Fertil Steril, 2005, 84: S441-S441.
21. Hirata T, Osuga Y, Hamasaki K, et al. Interleukin (IL)-17A stimulates IL-8 secretion, cyclooxygenase-2 expression, and cell proliferation of endometriotic stromal cells [J]. Endocrinology, 2008, 149: 1260-1267. (Pubitemid 351397970)
22. Yang ZO, Hirota Y, Osuga Y, et al. Interleukin-4 stimulates proliferation of endometriotic stromal cells [J]. Am J Pathol, 2008, 173: 463-469.
23. Hirota Y, Osugal Y, Hirata T, et al. Activation of protease-activated receptor 2 stimulates proliferation and interleukin (IL)-6 and IL-8 secretion of endometriotic stromal cells [J]. Hum Reprod, 2005, 20: 3547-3553.
24. Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease [J]. Pharmacol Ther, 2007, 116: 192-206. (Pubitemid 47451511)
25. Mayer RJ, Callahan JF. p38 MAP kinase inhibitors: a future therapy for inflammatory diseases [J]. Drug Discov Today, 2006, 3: 49-54.
26. Malemud CJ. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways [J]. Curr Opin Pharmacol, 2007, 7: 339-343. (Pubitemid 46731194)
27. Behr TM, Berova M, Doe CP, et al. p38 Mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease [J]. Curr Opin Investig Drugs, 2003, 4: 1059-1064. (Pubitemid 37321399)
28. Phd CG, Md RM, Merica E, et al. The pharmacokinetics (PK) and pharmacodynamics (PD) of VX-702, a novel, oral p38MAP kinase inhibitor, in healthy volunteers [J]. Clin Pharmacol Ther, 2004, 75: P52.
29. Miwatashi S, Arikawa Y, Kotani E, et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1, 3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent [J]. J Med Chem, 2005, 48: 5966-5979. (Pubitemid 41324607)
30. Chen KH, Weng MS, Lin JK. Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells [J]. Biochem Pharmacol, 2007, 73: 215-227.
31. Lu Q, Qiu TQ, Yang H. Ligustilide inhibits vascular smooth muscle cells proliferation [J]. Eur J Pharmacol, 2006, 542: 136-140. (Pubitemid 44066356)
32. Wang J, Huang H, Liu P, et al. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats [J]. Eur J Pharmacol, 2006, 553: 297-303. (Pubitemid 44779584)
33. Wang LH, Wu GL, Zhang LX, et al. Effects of fluvastatin on the activation of p38 mitogen-activated protein kinase in glomerular mesangial cells under high concentration of glucose [J]. Acta Pharm Sin, 2009, 44: 121-125.
34. Yoshino O, Osuga Y, Koga K, et al. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model [J]. J Reprod Immunol, 2006, 72: 85-93. (Pubitemid 44711877)